Subscriber ContentRead Preview
Shares hit a 52-week high as the tax preparation company's quarterly results wowed Wall Street. Expect more gains.
Tech Trader Daily by Tiernan Ray
Subscriber Content Read Preview
Video game sales fell 5% year-over-year in January; however, PS3 titles stood out.
Subscriber Content Read Preview
Brocade and Intuit rose while Campbell Soup and JDS Uniphase fell.
Subscriber Content Read Preview
Deutsche Bank ups its target on the travel booking website's stock to $490.
Subscriber Content Read Preview
Credit Suisse likes WellPoint, Unitedhealth, Coventry and Humana.
Subscriber Content Read Preview
The graphics-chip firm has an upbeat outlook.
Subscriber Content Read Preview
China Telecom is taking preorders but China Mobile has other ideas.
Subscriber Content Read Preview
Investors pour money into domestic mutual funds with stocks at highs. Contrarians, beware.
Subscriber Content Read Preview
Goldman Sachs tells clients to prepare for the retail stock to make a big move in response to the next earnings report.
Subscriber Content Read Preview
Japanese currency shows signs of significant weakening ahead as economy falls to No. 3 and as its debt burgeons.
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
Subscriber Content Read Preview
The tech titan tops our global ranking for the second straight year, followed by Amazon and Berkshire Hathaway.
Editor and President Ed Finn explains how you can use Barron's to become a better investor. Watch video
QQQQ | INTU | RTN | APOL | PCLN |
GDX | RST | ALU | BNO | CAB |
COOL | BRCD | HAL | BLK | CSIQ |
ARMH | AAPL | CRM | AMZN | MA |
Subscriber Content Read Preview
Slowing growth abroad will likely be a drag for the U.S.
The chief investment officer of Rosenau/Paul thinks the time is finally here for large-cap stocks with growing dividends. Here's what she's been buying.
Regardless of what path Egypt now follows, a leading analyst says the price of oil is headed toward $300 a barrel based on basic supply-and-demand forces.
With drug stocks ailing, companies like Abbott and Medtronic should start shedding non-core businesses. For investors, it would be just the right medicine.
Business ethicists and advocates for corporate social responsibility are playing a dangerous game.
This feature tracks the performance of stocks Barron's has written about during 2011 -- both favorably and critically. For stocks featured in Barron's print magazine, prices are measured from the Friday before publication date to their current price. For stocks featured on Barrons.com, prices are measured from the trading day of publication date to their current price. This list includes U.S. stocks only, including ADRs, but not foreign stocks.